title: Do platinum salts fit all triple negative breast cancers?
abstract: Triple-negative breast cancer (TNBC) is an aggressive disease with limited treatment options and poor prognosis once metastatic. Pre-clinical and clinical data suggest that TNBC could be more sensitive to platinum-based chemotherapy, especially among BRCA1/2-mutated patients. In recent years, several randomised trials have been conducted to evaluate platinum efficacy in both early-stage and advanced TNBC, with conflicting results especially for long-term outcomes. Experimental studies are now focusing on identifying biomarkers of response to help selecting patients who may benefit most from platinum-based therapies, including BRCA1/2 mutational status and genomic instability signatures (such as HRD-LOH or HRD-LST scores). A standard therapy for TNBC is still missing and platinum-based regimens represent an emerging therapeutic option for selected patients with a defect in the homologous recombination repair system. The identification of these patients through validated biomarker assays will be crucial to optimize the use of currently approved agents in TNBC.
authors.affiliation: Department of Medical and Biological Sciences, University of Udine, Udine, Italy; Department of Medical Oncology, University Hospital of Udine, Udine, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Gerratana
authors.affiliation: Department of Medical and Biological Sciences, University of Udine, Udine, Italy; Department of Medical Oncology, University Hospital of Udine, Udine, Italy.
authors.forename: V
authors.initials: V
authors.lastname: Fanotto
authors.affiliation: Department of Medical and Biological Sciences, University of Udine, Udine, Italy; Department of Medical Oncology, University Hospital of Udine, Udine, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Pelizzari
authors.affiliation: Department of Medical Oncology, University Hospital of Udine, Udine, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Agostinetto
authors.affiliation: Department of Medical and Biological Sciences, University of Udine, Udine, Italy; Department of Medical Oncology, University Hospital of Udine, Udine, Italy. Electronic address: fabio.puglisi@uniud.it.
authors.forename: F
authors.initials: F
authors.lastname: Puglisi
mesh_terms: D019313:BRCA1 Protein / Q000235:genetics; D024682:BRCA2 Protein / Q000235:genetics; D005260:Female; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D006801:Humans; D009944:Organoplatinum Compounds / Q000737:chemistry / Q000627:therapeutic use*; D051135:Rad51 Recombinase / Q000235:genetics; D016032:Randomized Controlled Trials as Topic; D064726:Triple Negative Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics
chemical_list: D019313:BRCA1 Protein; C492913:BRCA1 protein, human; D024682:BRCA2 Protein; C551750:BRCA2 protein, human; D009944:Organoplatinum Compounds; C495153:RAD51 protein, human; D051135:Rad51 Recombinase
keywords: BRCAness; Carboplatin; Cisplatin; Triple negative breast cancer